152 related articles for article (PubMed ID: 11606406)
1. HDM2 protein overexpression, but not gene amplification, is related to tumorigenesis of cutaneous melanoma.
Polsky D; Bastian BC; Hazan C; Melzer K; Pack J; Houghton A; Busam K; Cordon-Cardo C; Osman I
Cancer Res; 2001 Oct; 61(20):7642-6. PubMed ID: 11606406
[TBL] [Abstract][Full Text] [Related]
2. Minichromosome maintenance protein expression in benign nevi, dysplastic nevi, melanoma, and cutaneous melanoma metastases.
Boyd AS; Shakhtour B; Shyr Y
J Am Acad Dermatol; 2008 May; 58(5):750-4. PubMed ID: 18249467
[TBL] [Abstract][Full Text] [Related]
3. TSLC1 expression discriminates cutaneous melanomas from dysplastic nevi.
You Y; Wang SH; Zhang JF; Zheng SY
Melanoma Res; 2012 Dec; 22(6):430-5. PubMed ID: 23047161
[TBL] [Abstract][Full Text] [Related]
4. Comparison of cellular protooncogene activation and transformation-related activity of human melanocytes and metastatic melanoma.
Husain Z; FitzGerald GB; Wick MM
J Invest Dermatol; 1990 Nov; 95(5):571-5. PubMed ID: 2121834
[TBL] [Abstract][Full Text] [Related]
5. Expression of insulin-like growth factor I (IGF-I) in nevi and melanomas.
Fleming MG; Howe SF; Graf LH
Am J Dermatopathol; 1994 Aug; 16(4):383-91. PubMed ID: 7978067
[TBL] [Abstract][Full Text] [Related]
6. HDM2 protein overexpression and prognosis in primary malignant melanoma.
Polsky D; Melzer K; Hazan C; Panageas KS; Busam K; Drobnjak M; Kamino H; Spira JG; Kopf AW; Houghton A; Cordon-Cardo C; Osman I
J Natl Cancer Inst; 2002 Dec; 94(23):1803-6. PubMed ID: 12464652
[TBL] [Abstract][Full Text] [Related]
7. Expression of microtubule-associated protein 2 in benign and malignant melanocytes: implications for differentiation and progression of cutaneous melanoma.
Fang D; Hallman J; Sangha N; Kute TE; Hammarback JA; White WL; Setaluri V
Am J Pathol; 2001 Jun; 158(6):2107-15. PubMed ID: 11395388
[TBL] [Abstract][Full Text] [Related]
8. Expression of the tumor suppressor gene product p16INK4 in benign and malignant melanocytic lesions.
Keller-Melchior R; Schmidt R; Piepkorn M
J Invest Dermatol; 1998 Jun; 110(6):932-8. PubMed ID: 9620301
[TBL] [Abstract][Full Text] [Related]
9. Automated quantitative analysis of HDM2 expression in malignant melanoma shows association with early-stage disease and improved outcome.
Berger AJ; Camp RL; Divito KA; Kluger HM; Halaban R; Rimm DL
Cancer Res; 2004 Dec; 64(23):8767-72. PubMed ID: 15574789
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical expression of vascular endothelial growth factor, matrix metalloproteinase 2, and matrix metalloproteinase 9 in cutaneous melanocytic lesions.
Simonetti O; Lucarini G; Brancorsini D; Nita P; Bernardini ML; Biagini G; Offidani A
Cancer; 2002 Nov; 95(9):1963-70. PubMed ID: 12404291
[TBL] [Abstract][Full Text] [Related]
11. Bim expression is reduced in human cutaneous melanomas.
Dai DL; Wang Y; Liu M; Martinka M; Li G
J Invest Dermatol; 2008 Feb; 128(2):403-7. PubMed ID: 17637819
[TBL] [Abstract][Full Text] [Related]
12. Quantitative analysis of melanocytic tissue array reveals inverse correlation between activator protein-2alpha and protease-activated receptor-1 expression during melanoma progression.
Tellez CS; Davis DW; Prieto VG; Gershenwald JE; Johnson MM; McCarty MF; Bar-Eli M
J Invest Dermatol; 2007 Feb; 127(2):387-93. PubMed ID: 16946713
[TBL] [Abstract][Full Text] [Related]
13. bcl-2 protein expression in melanocytic neoplasms of the skin.
Ramsay JA; From L; Kahn HJ
Mod Pathol; 1995 Feb; 8(2):150-4. PubMed ID: 7777475
[TBL] [Abstract][Full Text] [Related]
14. Extra c-myc oncogene copies in high risk cutaneous malignant melanoma and melanoma metastases.
Kraehn GM; Utikal J; Udart M; Greulich KM; Bezold G; Kaskel P; Leiter U; Peter RU
Br J Cancer; 2001 Jan; 84(1):72-9. PubMed ID: 11139316
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical detection of p53 in melanomas with rare p53 gene mutations is associated with mdm-2 overexpression.
Poremba C; Yandell DW; Metze D; Kamanabrou D; Böcker W; Dockhorn-Dworniczak B
Oncol Res; 1995; 7(7-8):331-9. PubMed ID: 8747596
[TBL] [Abstract][Full Text] [Related]
16. Proto-oncogene c-kit expression in malignant melanoma: protein loss with tumor progression.
Montone KT; van Belle P; Elenitsas R; Elder DE
Mod Pathol; 1997 Sep; 10(9):939-44. PubMed ID: 9310959
[TBL] [Abstract][Full Text] [Related]
17. Bcl-2 expression in human melanocytes and melanocytic tumors.
van den Oord JJ; Vandeghinste N; De Ley M; De Wolf-Peeters C
Am J Pathol; 1994 Aug; 145(2):294-300. PubMed ID: 8053490
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical analysis of Bcl-2 protein regulation in cutaneous melanoma.
Tron VA; Krajewski S; Klein-Parker H; Li G; Ho VC; Reed JC
Am J Pathol; 1995 Mar; 146(3):643-50. PubMed ID: 7534042
[TBL] [Abstract][Full Text] [Related]
19. Survivin protein in UVB induced apoptosis of melanoma cells and in melanoma progression.
Zhang H
Oncol Rep; 2005 Jun; 13(6):1121-6. PubMed ID: 15870931
[TBL] [Abstract][Full Text] [Related]
20. Expression of thyrotropin-releasing hormone by human melanoma and nevi.
Ellerhorst JA; Naderi AA; Johnson MK; Pelletier P; Prieto VG; Diwan AH; Johnson MM; Gunn DC; Yekell S; Grimm EA
Clin Cancer Res; 2004 Aug; 10(16):5531-6. PubMed ID: 15328193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
